MacroGenics, Inc.

MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer

MacroGenics reported positive interim Phase 2 LINNET data for lorigerlimab, a bispecific PD-1/CTLA-4 DART molecule, in advanced clear cell gynecologic cancer, presented at the ESMO 2026 Congress. Among 16 response-evaluable CCGC patients, confirmed ORR was 25% (4/16) with a 44% disease control rate and all responses ongoing at the September 1, 2026 cutoff; median PFS was 2.9 months. Safety was manageable but meaningful: Grade ≥3 treatment-related adverse events occurred in 49% of all 41 patients, one Grade 5 TRAE in the PROC cohort, and 24% discontinued due to TRAEs. MacroGenics is enrolling 20 additional CCGC patients at a lower 3 mg/kg Q3W dose, with updated LINNET results expected in the first half of 2027.

•6d ago

MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN

MacroGenics reported positive interim Phase 1 data for MGC026, a B7-H3-directed ADC, presented at the ESMO 2026 Congress. In heavily pretreated SCCHN patients, MGC026 achieved a 27% best overall response rate (6/22) with a 64% disease control rate, and no treatment-related discontinuations, ILD, pneumonitis or ocular toxicity were observed. Across the dose-escalation population, confirmed ORR was 29% with durable responses (median DOR 10.2 months), supporting selection of 7.5 mg/kg Q3W for expansion cohorts. MacroGenics plans to initiate a front-line SCCHN cohort combining MGC026 with pembrolizumab in early 2027, with Stage 2 data expected mid-2027.

•9d ago

MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid Tumors

MacroGenics dosed the first patient in a Phase 1 study of MGC030, a first-in-class antibody-drug conjugate targeting an undisclosed antigen, in patients with advanced solid tumors. The open-label dose-escalation and cohort-expansion trial will enroll up to 54 participants initially, spanning urothelial, colorectal, gastric, esophageal, and pancreatic cancers. MGC030 becomes MacroGenics' third ADC in active clinical development, using Synaffix technology with an exatecan-based linker-payload at a drug-to-antibody ratio of 4.

•17d ago

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

MacroGenics reported Q2 revenue of $32.8 million, up from $6.9 million a year ago, driven by a $24.5 million milestone payment from Sanofi. The company completed the sale of its manufacturing operations to Bora for $119.6 million, transitioning to a fully outsourced model and targeting a workforce reduction to approximately 140 employees. Pro forma cash of $327 million extends the cash runway into 2028, supporting ongoing clinical studies for MGC026, MGC028, and lorigerlimab.

•2mo ago

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

MacroGenics announced that Gilead Sciences has exercised an option to license a preclinical bispecific program, triggering a $10 million payment to MacroGenics under their existing collaboration agreement. The licensed program utilizes MacroGenics' TRIDENT platform to target solid tumors and is the second preclinical program to be advanced under the 2022 partnership alongside the clinical-stage MGD024. MacroGenics remains eligible to receive up to approximately $1.6 billion in future milestone payments as well as royalties on sales of products developed from the collaboration programs.

•2mo ago

MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026

MacroGenics reported that its lead asset MGC026 achieved the pre-specified response threshold in the SCCHN cohort, triggering Stage 2 enrollment of the ongoing Phase 1 study. A total of 74 patients have been enrolled across dose escalation and expansion cohorts with no reports of interstitial lung disease or ocular toxicity observed to date. The company plans to present detailed data at the ESMO 2026 Congress in October, alongside a separate poster for its bispecific candidate lorigerlimab.

•3mo ago

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

MacroGenics completed the sale of its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million in upfront cash. The transaction includes the transfer of facilities in Rockville and Frederick, Maryland, and approximately 140 employees to Bora, which will now handle manufacturing for MacroGenics under a new supply agreement. This strategic shift allows MacroGenics to reduce operational costs and focus resources on its clinical pipeline of antibody-based cancer therapeutics.

•4mo ago

MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval

MacroGenics announced it will receive a $24.5 million regulatory milestone payment from partner Sanofi following the FDA's accelerated approval of TZIELD for delaying insulin decline in children aged 8 to 17 with stage 3 type 1 diabetes. Under the collaboration agreement, MacroGenics remains eligible to receive up to $305 million in additional milestone payments and retains single-digit royalty rights on global net sales above a specified threshold. The FDA approval expands the therapeutic potential of TZIELD, marking a significant commercial step for the asset which was previously approved for stage 2 type 1 diabetes.

•4mo ago

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

MacroGenics reported Q1 2026 revenue of $20.8 million, a 57.5% increase from the same period in 2025. The company announced the divestiture of its manufacturing operations to Bora Pharmaceuticals, which is expected to provide an upfront payment of $122.5 million and extend its cash runway through 2028. MacroGenics also expanded its ZYNYZ royalty monetization with Sagard Healthcare Partners, receiving $60.0 million and potentially up to $20.0 million more based on 2026 sales performance. The company's clinical-stage ADC programs, MGC026 and MGC028, continue to show acceptable safety profiles and evidence of anti-tumor activity, with initial data expected in mid-2026 and the second half of 2026, respectively.

•5mo ago

MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals

MacroGenics will sell its GMP drug substance manufacturing operations to Bora Pharmaceuticals for an upfront payment of $122.5 million. The transaction includes the transfer of the manufacturing site, CDMO operations, and associated personnel to Bora, with the deal expected to close in Q3 2026. MacroGenics will maintain a supply arrangement with Bora to support its internal pipeline needs, while Bora aims to expand its North American biologics operation.

•5mo ago

MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement

MacroGenics expanded its royalty purchase agreement with Sagard Healthcare Partners for ZYNYZ, securing a $60 million upfront payment. The company may receive an additional $20 million in 2026 sales-based milestones, while royalty rights revert to MacroGenics once Sagard achieves a 1.7x or 2.0x return on investment. ZYNYZ is a PD-1 inhibitor licensed to Incyte for the treatment of anal canal and Merkel cell carcinomas.

•5mo ago